Nimodipine (Synonyms: BAY-e 9736)

Name: Nimodipine
Brand: MedChemExpress
SKU: HY-B0265
Rating: 5.0 (21 reviews)

Cat. No.: HY-B0265 Purity: 99.86%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive dihydropyridine calcium antagonist. Nimodipine can be used for the research of cerebrovascular disorders.

For research use only. We do not sell to patients.

CAS No. : 66085-59-4

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
100 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	In-stock	Estimated Time of Arrival: December 31
5 g	Get quote
10 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 21 publication(s) in Google Scholar

Other Forms of Nimodipine:

(R)-Nimodipine In-stock
(S)-Nimodipine In-stock
Nimodipine-d₇ In-stock
Nimodipine (Standard) Get quote

21 Publications Citing Use of MCE Nimodipine

In Vivo Efficacy Study

Histological Imaging/Staining

: Nimodipine purchased from MedChemExpress. Usage Cited in: Aging Cell. 2024 Aug 15:e14305. [Abstract]; Timeline for ABR testing and drug treatment. Nimodipine was administered subcutaneously to 7-month-old WT mice at a dose of 5 mg/kg or 10 mg/kg every other day for 60 days.

: Nimodipine purchased from MedChemExpress. Usage Cited in: Aging Cell. 2024 Aug 15:e14305. [Abstract]; Timeline for ABR testing and drug treatment. Nimodipine was administered subcutaneously to 7-month-old WT mice at a dose of 5 mg/kg or 10 mg/kg every other day for 60 days. Representative ABR waveforms in response to click stimuli (90-30 dB) in mice.

: Nimodipine purchased from MedChemExpress. Usage Cited in: Aging Cell. 2024 Aug 15:e14305. [Abstract]; Timeline for ABR testing and drug treatment. Nimodipine was administered subcutaneously to 7-month-old WT mice at a dose of 5 mg/kg or 10 mg/kg every other day for 60 days. ABR threshold to click stimuli in the AHL, solvent, and Nimodipine (5, 10 mg/kg) treatment groups.

: Nimodipine purchased from MedChemExpress. Usage Cited in: Aging Cell. 2024 Aug 15:e14305. [Abstract]; Timeline for ABR testing and drug treatment. Nimodipine was administered subcutaneously to 7-month-old WT mice at a dose of 5 mg/kg or 10 mg/kg every other day for 60 days. ABR threshold to pure-tone in the AHL, solvent, and Nimodipine (5, 10 mg/kg) treatment groups.

: Nimodipine purchased from MedChemExpress. Usage Cited in: Aging Cell. 2024 Aug 15:e14305. [Abstract]; Immunofluorescence of IHCs and ribbon synapses in the apex, middle, and base of cochlea from WT 9 M mice, solvent-treated, and Nimodipine (5, 10 mg/kg)-treated mice.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Calcium Channel Isoform Specific Products:

View All Isoforms

N-type calcium channel L-type calcium channel P/Q-type calcium channel T-type calcium channel Calcium Channel

Biological Activity
Purity & Documentation
References
Customer Review

Description

Nimodipine (BAY-e 9736) is an orally active, well-tolerated and light-sensitive dihydropyridine calcium antagonist. Nimodipine can be used for the research of cerebrovascular disorders^[1].

IC₅₀ & Target

dihydropyridine calcium^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	0.8 μM Compound: 54	Agonist activity at mouse TRPA1 channel expressed in CHO cells assessed as increase in intracellular calcium influx Agonist activity at mouse TRPA1 channel expressed in CHO cells assessed as increase in intracellular calcium influx	[PMID: 20356305]
HEK293	IC₅₀	0.11 μM Compound: Nimodipine	Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit	[PMID: 22761000]
HepG2	EC₅₀	0.39 μM Compound: 5	Agonist activity at PXR (unknown origin) expressed in human HepG2 cells assessed as induction of CYP3A4 transactivation after 16 hrs by luciferase reporter gene assay Agonist activity at PXR (unknown origin) expressed in human HepG2 cells assessed as induction of CYP3A4 transactivation after 16 hrs by luciferase reporter gene assay	[PMID: 23688559]
LLC-MK2	IC₅₀	32.31 μM Compound: Nimodipine	Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi infected in rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay Antitrypanosomal activity against trypomastigotes of Trypanosoma cruzi infected in rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay	[PMID: 20934347]
LLC-MK2	IC₅₀	96.19 μM Compound: Nimodipine	Cytotoxicity against rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay Cytotoxicity against rhesus monkey LLC-MK2 cells after 48 hrs by MTT assay	[PMID: 20934347]
PC-12	EC₅₀	1.29 μg/mL Compound: Nimodipine	Anti-anoxic activity in rat PC12 cells reduction in assessed as sodium hydrosulfite-induced cell injury Anti-anoxic activity in rat PC12 cells reduction in assessed as sodium hydrosulfite-induced cell injury	[PMID: 31317731]
PC-12	EC₅₀	97.3 μM Compound: Nimodipine	Neuroprotective activity against glutamate-induced neuronal cell death in rat PC12 cells assessed as increase in cell viability pretreated for 2 hrs followed by glutamate challenge measured after 24 hrs by MTT assay Neuroprotective activity against glutamate-induced neuronal cell death in rat PC12 cells assessed as increase in cell viability pretreated for 2 hrs followed by glutamate challenge measured after 24 hrs by MTT assay	[PMID: 29775304]
SH-SY5Y	IC₅₀	14 μM Compound: Nimodipine	Inhibition of K+-induced voltage gated calcium channel opening in human SH-SY5Y cells assessed as decrease in Ca2+ level after 10 mins by Fluo-4 dye-based fluorescence assay Inhibition of K+-induced voltage gated calcium channel opening in human SH-SY5Y cells assessed as decrease in Ca2+ level after 10 mins by Fluo-4 dye-based fluorescence assay	[PMID: 30530190]
Ventricular myocyte	IC₅₀	0.3 μM Compound: Nimodipine	Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes	[PMID: 22761000]

In Vitro

Nimodipine (1.5~150 μg/ml; 15 minutes; B16a and W256 cells) results in a dose-dependent inhibition of B16a and W256 tumor-cell-induced platelet aggregation. Nimodipine is also inhibitory in a homologous system^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Nimodipine (0.2 μg/μl, intrathecal administration) prevents subarachnoid hemorrhage-associated cerebral vasospasm by prophylactic continuous intrathecal administration^[2].
Nimodipine(0.1~80 mg/kg; p.o.) results in a significant dose-dependent inhibition of spontaneous metastasis^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	New Zealand white rabbits^[2]
Dosage:	0.2 µg/µl
Administration:	Intrathecal administration
Result:	Prevented subarachnoid hemorrhage-associated cerebral vasospasm by prophylactic continuous intrathecal administration.

Clinical Trial

Molecular Weight

418.44

Formula

C₂₁H₂₆N₂O₇

CAS No.

66085-59-4

Appearance

Solid

Color

Light yellow to yellow

SMILES

O=C(C1=C(C)NC(C)=C(C(OC(C)C)=O)C1C2=CC=CC([N+]([O-])=O)=C2)OCCOC

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (238.98 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.3898 mL	11.9491 mL	23.8983 mL
5 mM	0.4780 mL	2.3898 mL	4.7797 mL
10 mM	0.2390 mL	1.1949 mL	2.3898 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.97 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (5.97 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.86%

Select Batch:

Data Sheet (278 KB) SDS (392 KB)

COA (254 KB) LCMS (96 KB)

Handling Instructions (2659 KB)

References

[1]. Langley, M.S., et al. Nimodipine. Drugs 37, 669–699 (1989).

[2]. Marbacher S, et al. Prevention of delayed cerebral vasospasm by continuous intrathecal infusion of glyceroltrinitrate and nimodipine in the rabbit model in vivo. Intensive Care Med. 2008;34(5):932-938. [Content Brief]

[3]. Honn KV, et al. Inhibition of tumor cell-platelet interactions and tumor metastasis by the calcium channel blocker, nimodipine. Clin Exp Metastasis. 1984;2(1):61-72. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.3898 mL	11.9491 mL	23.8983 mL	59.7457 mL
	5 mM	0.4780 mL	2.3898 mL	4.7797 mL	11.9491 mL
	10 mM	0.2390 mL	1.1949 mL	2.3898 mL	5.9746 mL
	15 mM	0.1593 mL	0.7966 mL	1.5932 mL	3.9830 mL
	20 mM	0.1195 mL	0.5975 mL	1.1949 mL	2.9873 mL
	25 mM	0.0956 mL	0.4780 mL	0.9559 mL	2.3898 mL
	30 mM	0.0797 mL	0.3983 mL	0.7966 mL	1.9915 mL
	40 mM	0.0597 mL	0.2987 mL	0.5975 mL	1.4936 mL
	50 mM	0.0478 mL	0.2390 mL	0.4780 mL	1.1949 mL
	60 mM	0.0398 mL	0.1992 mL	0.3983 mL	0.9958 mL
	80 mM	0.0299 mL	0.1494 mL	0.2987 mL	0.7468 mL
	100 mM	0.0239 mL	0.1195 mL	0.2390 mL	0.5975 mL

Nimodipine Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Nimodipine66085-59-4BAY-e 9736AutophagyCalcium ChannelCa2+ channelsCa channelsorallywell-toleratedlight-sensitivedihydropyridinecalciumcerebrovascularInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

Nimodipine (Synonyms: BAY-e 9736)

Customer Review

Other Forms of Nimodipine:

Nimodipine Related Antibodies

21 Publications Citing Use of MCE Nimodipine

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Calcium Channel Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

Nimodipine Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

Nimodipine Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report